Delft-based OASYS NOW, a legal-tech, cyber-security and data-sharing solutions startup, announced on Wednesday that it has raised €250K in a fresh round of funding.
The investment came from Graduate Entrepreneur Fund, TenNine.VC, Golden Egg Check Capital, and several angel investors.
Thomas Mensink from Golden Egg Check Capital says, “The unique approach from the OASYS NOW team to include the citizens directly in the process of Personalised Medicine research and empowering them with control over who they want to share their data with is very inspiring. This is why we support this company and put our trust in the team!”
What does OASYS NOW offer?
Founded in 2018 by Nima Salami, a student in Rotterdam, and later joined by co-founders Soroosh Torabi, Sara Okhuijsen and Francis Behnen, OASYS NOW is a cybersecurity and intelligent data storage and analysis solutions company.
It offers ethical, privacy-first, and future-proof data processes and storage solutions for biotech and high-security organisations in the health and genomics sector to accelerate the implementation of medical research and therapy.
When using common testing services like 23andMe or others, people generally agree to the sale of their DNA and health information for research purposes.
In order to enable patients and people to manage their health and DNA data and take part in clinical trials and scientific research on a global scale, OASYS NOW has developed a software platform.
The platform enables its clients to manage how their health data is used, who has access to it, and how to profit from the study of such priceless data by employing blockchain technology, such that they can participate in clinical studies and scientific research worldwide.
With the consent of research participants, researchers can access their health information in a secure and safe setting, enabling them to provide patients with more individualised and effective therapies that enhance their quality of life and overall health.
The company works with organisations such as health testing companies, disease research foundations, and academic medical centres to ensure that data sharing is secure and that all protocols are followed.
Capital utilisation
In order to move closer to its goal of ensuring that Personalised Medicine is available to everyone worldwide, OASYS NOW claims it would utilise the funds to increase its workforce and accelerate the development of its services.
Co-founder Nima Salami says, “It is very exciting that institutional and reputable angel & VC investors are supporting our mission to help expand the Digital Health Data & Personalised Medicine accessibility worldwide for everyone!”
01
From port to startup fort: How Lars Crama is ‘Making it Happen’ in Rotterdam